Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development
Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
Marinomed enters first long-term Solv4U partnership with Shanghai-based SPH Sine Pharmaceutical Laboratories Co. Ltd.
Lucia Ziegler, MSc
IR & PR Manager